HOUSTON, TX, USA I4, 2025 I ImmunoMet Therapeutics, Inc., (“ImmunoMet”, or the “Company”), a clinical stage biotechnology company committed to ...
BAGSVAERD, Denmark I4, 2025 I Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 ...
EXUMA now advancing its clinically de-risked solid tumor & hematologic CARs with in vivo GCAR ™ platform and SCL mRNA technology WEST PALM BEACH, FL, USA I3, 2025 I EXUMA Biotech, Corp., a ...
The U.S. Food and Drug Administration (FDA) has granted andecaliximab a Rare Pediatric Disease Designation (RPDD) for the treatment of FOP. An RPDD designation is granted to potential treatments for ...
DURHAM, NC, USA I2, 2025 I IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human ...
CAMBRIDGE, MA, USA & BRISBANE, Australia I2, 2025 I Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density ...
Trial aims to establish safety and provide proof of concept for GYS1 inhibition as promising new treatment strategy in patients with late-onset Pompe disease ...
PRINCETON, NJ, USA I3, 2025 I Ymmunobio (YB) is excited to share that they in collaboration with the Paul Scherrer Institute (PSI) have received ...
NORTH CHICAGO, IL and SAN DIEGO, CA, USA I3, 2025 I AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and ...
Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a ...
GAITHERSBURG, MD, USA I2, 2025 I Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today ...
Novel breakthrough: first molecule to modulate the fundamental mechanism of T cell activation underlying autoimmune pathology ...